Skip navigation
Please use this identifier to cite or link to this item: http://repositorio.unb.br/handle/10482/28692
Files in This Item:
File SizeFormat 
0037-8682-rsbmt-00-00-31.pdf
???org.dspace.app.webui.jsptag.ItemTag.accessRestricted???
741,15 kBAdobe PDF ???org.dspace.app.webui.jsptag.ItemTag.restrito???
Title: Treatment of American tegumentary leishmaniasis in special populations: a summary of evidence
Authors: Silva, Juliana Saboia Fontenele e
Galvao, Tais Freire
Pereira, Maurício Gomes
Silva, Marcus Tolentino
Assunto:: American tegumentary leishmaniasis
Special populations
Treatment
Evidence
Issue Date: 2013
Publisher: Sociedade Brasileira de Medicina Tropical - SBMT
Citation: Rev. Soc. Bras. Med. Trop.,v.46,n.6,p.669-677,2013
Abstract: We aimed to assess and synthesize the information available in the literature regarding the treatment of American tegumentary leishmaniasis in special populations. We searched MEDLINE (via PubMed), EMBASE, LILACS, SciELO, Scopus, Cochrane Library and mRCT databases to identify clinical trials and observational studies that assessed the pharmacological treatment of the following groups of patients: pregnant women, nursing mothers, children, the elderly, individuals with chronic diseases and individuals with suppressed immune systems. The quality of evidence was assessed using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach. The available evidence suggests that the treatments of choice for each population or disease entity are as follows: nursing mothers and children (meglumine antimoniate or pentamidine), patients with renal disease (amphotericin B or miltefosine), patients with heart disease (amphotericin B, miltefosine or pentamidine), immunosuppressed patients (liposomal amphotericin), the elderly (meglumine antimoniate), pregnant women (amphotericin B) and patients with liver disease (no evidence available). The quality of evidence is low or very low for all groups. Accurate controlled studies are required to fill in the gaps in evidence for treatment in special populations. Post-marketing surveillance programs could also collect relevant information to guide treatment decision-making.
DOI: https://dx.doi.org/10.1590/0037-8682-0104-2013
Appears in Collections:Uso interno - em processamento

Show full item record Recommend this item " class="statisticsLink btn btn-primary" href="/handle/10482/28692/statistics">



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.